SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB



(Mark one)

[XX] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
     Act of 1934.

For the period ended June 30, 1999.

[_]  Transition  Report  Pursuant  to  Section  13 or  15(d)  of the  Securities
     Exchange Act of 1934.

For the transition period from__ to__.



Commission File Number:                                               0-16128

                              TUTOGEN MEDICAL, INC.
             (Exact name of registrant as specified in its charter)

Florida                                                            59-3100165
(State or other Jurisdiction of                                (I.R.S. Employer
Incorporation or Organization)                               Identification No.)


1719 Route 10, Suite 314, Parsippany, New Jersey                        07054
(Address of Principal Executive Offices)                              (Zip Code)


Registrant's telephone number, including area code:            (973) 359-8444


Securities registered pursuant to Section 12(b) of the Act:              None


Securities registered pursuant to Section 12(g) of the Act:


   Common Stock, par value $.01
         (Title of Class)            (Name of Each Exchange on Which Registered)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding  months  (or for such  shorter  period  that the  Registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. Yes X No_.

As of July 31, 1999 there were outstanding 10,853,188 shares of Tutogen Medical,
Inc. Common Stock, par value $0.01.



<PAGE>


                     TUTOGEN MEDICAL, INC. AND SUBSIDIARIES

                                      INDEX



PART I.             Financial Information.

          ITEM 1.   Financial Statements.

                    Consolidated  Balance Sheets - June 30, 1999 and           1
                    September 30, 1998.

                    Consolidated  Statements of  Operations  for the           2
                    three and nine months ended June 30, 1999
                    and 1998.

                    Consolidated  Statements of Cash Flows for the nine        3
                    months ended June 30, 1999 and
                    1998.

                    Notes to Consolidated Financial Statements.                4

          ITEM 2.   Management's Discussion and Analysis of                    6
                    Financial Condition and Results of
                    Operations.

PART II. Other Information.


          ITEM 6.   Exhibits and Reports on Form 8-K                           9

SIGNATURES                                                                    10



<PAGE>

                          PART I. FINANCIAL INFORMATION

Item 1.  Financial Statements.



                            TUTOGEN MEDICAL, INC. AND
                                  SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS
                                 (in thousands)

<TABLE>
<CAPTION>
                                                  (unaudited)        (audited)
                                                    June 30,       September 30,
                                                      1999             1998
                                                  -----------      -------------
<S>                                                 <C>               <C>
ASSETS

Current Assets
    Cash and cash equivalents                       $      278        $
                                                                             357
    Accounts receivable                                  1,777             1,685
    Inventories                                          4,440             4,435
    Other current assets                                   211               173
                                                    ----------        ----------

                                                         6,706             6,650

Property, plant and equipment, net                       2,547             2,995

Intangible and other assets, net                           279               596
                                                    ----------        ----------
TOTAL ASSETS                                        $    9,532        $   10,241
                                                    ==========        ==========


LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities
    Accounts payable                                $      652        $    1,010
    Accrued interest                                       136               189
    Other accrued expenses                                 874               953
    Revolving credit arrangements                        1,018               895
    Current portion of long-term debt                       70               162
                                                    ----------        ----------
                                                         2,750             3,209

Other Liabilities
    Long-term debt                                       1,406             3,644
    Other long-term obligations                             15                17

Shareholders' Equity                                     5,361             3,371
                                                    ----------        ----------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY          $    9,532        $   10,241
                                                    ==========        ==========
</TABLE>


See accompanying Notes to Consolidated Financial Statements.


                                        1

<PAGE>


                            TUTOGEN MEDICAL, INC. AND
                                  SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                            (in thousands except per
                                   share data)


<TABLE>
<CAPTION>
                                         Three Months Ended June 30,     Nine Months Ended June 30,

                                             1999            1998           1999            1998
                                             ----            ----           -----           ----
<S>                                      <C>             <C>             <C>             <C>
OPERATING REVENUES
          Revenue                        $      2,549    $      2,348    $      7,822    $      6,261
          Cost of revenue                       1,416           1,124           4,506           3,386
                                         ------------    ------------    ------------    ------------

             Gross margin                       1,133           1,224           3,316           2,875


OPERATING EXPENSES
         General and administrative               509             564           1,564           1,425
         Distribution and marketing               483             404           1,489           1,071
         Research and development                  74              77             279             200
         Depreciation and amortization            114             167             361             523
                                         ------------    ------------    ------------    ------------
                                                1,180           1,212           3,693           3,219

Operating (loss) profit                           (47)             12            (377)           (344)


License fee                                      --              --              --              (200)
Settlement of partnership interest               --              (205)           --              (205)
Other (income) expenses                            13              (4)           (133)            (58)
Interest expense                                   45              98             183             278
                                         ------------    ------------    ------------    ------------
                                                   58            (111)             50            (185)

                                         ------------    ------------    ------------    ------------
Net (loss) profit before income taxes            (105)            123            (427)           (159)

Income taxes                                     --              --              --              --
                                         ------------    ------------    ------------    ------------

NET (LOSS) PROFIT                        $       (105)   $        123    $       (427)   $       (159)
                                         ============    ============    ============    ============

Average common shares outstanding          10,851,707       5,316,570       8,925,453       5,017,178
                                         ============    ============    ============    ============

Net (loss) profit per share              $      (0.01)   $       0.02    $      (0.05)   $      (0.03)
                                         ============    ============    ============    ============
</TABLE>


See accompanying Notes to Consolidated Financial Statements


                                       2

<PAGE>


                            TUTOGEN MEDICAL, INC. AND
                                  SUBSIDIARIES
                      CONSOLIDATED STATEMENT OF CASH FLOWS
                                 (in thousands)
<TABLE>
<CAPTION>

                                                                    Nine Months Ended June 30,
                                                                  -----------------------------
                                                                     1999               1998
                                                                  ----------         ----------
<S>                                                                <C>               <C>
Cash flows from operating activities
Net loss                                                           $  (427)          $  (159)
Adjustments to reconcile net loss to net cash
  used in operating activities:
  Depreciation and amortization                                        583               784
  Increase (decrease) in cash resulting from changes in:
     Accounts receivable                                               (92)             (168)
     Inventories                                                        (5)           (1,353)
     Prepaid expenses and other current assets                         (38)              (58)
     Accounts payable and accrued liabilities                         (169)             (109)
                                                                   -------           -------
        Net cash used in operating activities                         (148)           (1,063)


Cash flows from investing activities
   Purchase of property, plant and equipment                          (176)             (128)
                                                                   -------           -------
      Net cash provided by (used in) investing activities             (176)             (128)

Cash flows from financing activities
    Issuance of stock                                                  458             4,295
    Proceeds from long-term borrowings                                 500
                                                                                     -------
    Proceeds (repayment) of short-term borrowings                      183            (3,946)
    Repayment of long-term debt                                        (48)             (129)
                                                                   -------           -------
         Net cash provided by financing activities                     593               720


Effect of exchange rate changes on cash                               (348)              (56)

Net decrease in cash and cash equivalents                              (79)             (527)

Cash and cash equivalents at beginning of period                       357               777
                                                                   -------           -------

Cash and cash equivalents at end of period                         $   278           $   250
                                                                   =======           =======


--------------------------------------------------------------------------------------------


Supplemental cash flow disclosures
      Interest paid                                                $   103           $   428
                                                                   =======           =======

Schedule of noncash financing activities:
      Issuance of common stock in exchange for
          convertible long-term debt and accrued interest          $ 2,162           $  --
      Issuance of common stock for interest                            376              --
                                                                   -------           -------
                                                                   $ 2,538           $  --
                                                                   =======           =======
</TABLE>

See accompanying Notes to Consolidated Financial Statements

                                        3

<PAGE>


                     TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
              NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
                                  June 30, 1999
                        (in thousands, except share data)


(1)  OPERATIONS AND ORGANIZATION

     Tutogen  Medical,  Inc.  along  with its  consolidated  subsidiaries  ("the
     Company")  processes,  manufactures  and  distributes  worldwide  specialty
     surgical  products  and  provides  tissue  processing  services  for neuro,
     orthopedic,    cardiovascular,    reconstructive   and   general   surgical
     applications.  The Company's core business is processing human donor tissue
     ("allografts") utilizing its patented Tutoplast(R) process for distribution
     to hospitals and surgeons.

(2)  SIGNIFICANT ACCOUNTING POLICIES

     The accompanying unaudited consolidated financial statements of the Company
     and the unaudited results of operations and cash flows for the three months
     ended  June  30,  1999 and 1998  have  been  prepared  in  conformity  with
     generally accepted accounting  principles for interim financial  reporting.
     Accordingly,  they do not include all of the information and notes required
     by  generally  accepted   accounting   principles  for  complete  financial
     statements.  In the opinion of  management,  all  adjustments  necessary in
     order to make the  financial  statements  not  misleading  have been  made.
     Operating results for the three and nine months ended June 30, 1999 are not
     necessarily  indicative of the results which may be expected for the fiscal
     year ending September 30, 1999. The interim financial  statements should be
     read in conjunction with the audited  consolidated  financial statements of
     the Company for the year ended September 30, 1998.


(3)  INVENTORIES

     Major  classes of inventory at June 30, 1999 and September 30, 1998 were as
     follows:

                                            June 30,        September 30,
                                             1999               1998

     Raw materials                          $ 1,362           $ 1,473
     Work in process                          2,787             2,729
     Finished goods                           1,142             1,249

     Less reserves for obsolescence            (851)           (1,016)
                                            -------           -------

                                            $ 4,440           $ 4,435
                                            -------           -------


                                        4

<PAGE>


(4)  SHAREHOLDERS' EQUITY

     On January 28, 1999, one of the Company's institutional investors converted
     its Convertible Debenture and accrued interest and expenses  (approximately
     $2,162)  into  4,600,507   shares  of  the  Company's   common  stock.   In
     consideration  of the  agreement  to  convert,  the  Company  issued to the
     investor 149,334 common shares as prepayment for one year's interest on the
     Debenture  and agreed to amend its  outstanding  Stock  Purchase  Warrants,
     totaling 1,353,957,  by reducing the exercise price from $2.50 per share to
     $1.25 per share if such  warrants  are  exercised  prior to June 30,  2000,
     after which date such warrants shall revert to their initial terms.

     During  the nine  months  ended  June 30,  1999,  this  same  institutional
     investor, a Director of the Company and private investors purchased 300,000
     Units,  100,000  Units and 57,500 Units,  respectively,  at $1.00 per Unit,
     each Unit  consisting  of one common  share of the  Company  and one Common
     Stock  Purchase  Warrant,  expiring March 31, 2000, at an exercise price of
     $1.50 per share.

(5)  DISTRIBUTION AGREEMENT

     On July 9, 1999, the Company entered into a Third Amendment to an Exclusive
     Distribution  Agreement with Mentor Corporation "Mentor" for the purpose of
     granting a license to Mentor to  exclusively  distribute  the  Tutoplast(R)
     Processed  Pericardium  ("Pericardium")  as an additional  product in their
     field  of  use  which  is  defined  as  all  urological  and  gynecological
     applications  and procedures in the United States and all foreign  markets.
     In addition, processing fees were modified on selected other products under
     the  Agreement.  The initial term of the  Pericardium  license is ten years
     with an automatic  renewal for successive terms of two full calendar years.
     The Company was paid a license fee of $300,000.


                                       5
<PAGE>


ITEM 2.   MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND
          RESULTS OF OPERATIONS (in thousands)

Results of Operations

Net Loss

Net loss for the three  months  ended June 30,  1999  totaled  $105 or $0.01 per
share as compared to a net income of $123 or $0.02 per share for the same period
a year ago.  The net loss for the nine  months  ended June 30,  1998 was $427 or
$0.05 per share as compared to a net loss of $159 or $0.03 per share.

Revenue and Cost of Revenue

Revenue for the three  months  ended June 30, 1999  increased  9% to $2,549 from
$2,348 for the comparable  period.  The US operation revenues were $1,105 or 55%
higher than the same period last year.  This is a direct result of its strategic
alliances with the Mentor Corporation and IOP, Inc. The International  operation
had a decrease in revenues of 7% from the same period last year due primarily as
a result of the delay in adapting  to revised  standards  for tissue  processing
issued by the  international  regulatory  body.  The revenue for the nine months
ended June 30,  1999  increased  25% to $7,822  from  $6,261 for the  comparable
period.  The revenues for the US  operation  were $3,123 or a 99% increase  from
$1,573  for the same  period  last  year.  The  revenues  for the  International
operation increased by 3% from the same period last year.

Gross  margins for the three months ended June 30, 1999 were 44% and 52% for the
comparable  period last year.  The gross  margins for the nine months ended June
30, 1999  decreased  to 42% from 46% for the  comparable  period last year.  The
decrease was primarily  attributable  to an unfavorable  mix of products sold at
both the US and International operations.

General and Administrative

General and  administrative  expenses  decreased  10% and  increased 10% for the
three and nine months ending June 30, 1999,  respectively,  from the  comparable
periods last year. The year-to-date increase was due primarily to an increase in
legal, consulting and travelling expenses.

Distribution and Marketing

Distribution and marketing expenses increased 20% and 39% for the three and nine
months  ending June 30, 1999,  respectively,  from the  comparable  periods last
year. The increase was primarily  associated with the building of a direct sales
force in Germany and the costs associated with the introduction of a new product
line, Tutoplast(R) bovine pericardium.

Research and Development

Research and development  expenses  decreased 4% and increased 40% for the three
and nine months ending June 30, 1999, respectively,  from the comparable periods
last year.  The  year-to-date  increase  was due to the  expansion  of the R & D
effort in  Germany  and  travelling  and  personnel  costs to expand  the tissue
recovery sites in Europe.


                                        6
<PAGE>


Depreciation and Amortization

Depreciation  and  amortization  decreased  32% and 31% for the  three  and nine
months  ending June 30, 1999,  respectively,  from the  comparable  periods last
year.  The  reduction in  depreciation  and  amortization  was  attributed to an
increase in fully depreciated property, plant and equipment.

Interest Expense

Interest  expense declined 54% and 34% for the three and nine months ending June
30, 1999,  respectively,  from the comparable  periods last year. Lower interest
was the direct  result of capital  restructurings  completed  during the quarter
ending  December 31, 1997 and the recent  conversion of $2,074 of long-term debt
to common stock at the end of January of 1999.

Liquidity and Capital Resources

At June 30, 1999 and  September  30,  1998 the  Company  had working  capital of
$3,956  and  $3,441,  respectively.   The  Company  maintains  revolving  credit
facilities totaling DM 2,360 (approximately  $1,250) with three German banks. At
June 30, 1999 the Company had borrowed $961 against these lines.

In the past the Company has relied upon its available  working capital lines and
institutional  investors to fund operational cash flow, when needed. During this
year, one of the Company's  institutional  investors,  a Director of the Company
and private investors  purchased 300,000 Units,  100,000 Units and 57,500 Units,
respectively, at $1.00 per Unit, each Unit consisting of one common share of the
Company and one Common Stock  Purchase  Warrant,  expiring March 31, 2000, at an
exercise  price of $1.50 per share.  In addition,  the Company is  continuing to
seek other  investors  to infuse  additional  capital  into the  Company.  While
management  believes that it will be  successful in securing new funding,  there
can be no  assurances  that it will be able to do so. Lack of new funding  along
with the inability to increase processing revenues could result in a curtailment
of operations in the future.

The Company's  ability to generate  positive  operational cash flow is dependent
upon increasing processing revenues through increased recoveries by tissue banks
in the U.S. and Europe,  and the development of additional  markets and surgical
applications  worldwide.  While the Company  believes  that it continues to make
progress  in  both  these  areas,  there  can  be no  assurances  that  changing
governmental  regulations  will not have a material adverse effect on results of
operations and cash flow.

Government Regulation

It has  previously  been  reported  in an SEC  filing  that  the  Food  and Drug
Administration ("FDA") has raised a concern about the potential for transmission
of  Creutzfeldt-Jacob  Disease ("CJD") from one lot of  Tutoplast(R)  Dura Mater
processed by the Company in Germany  before April 1994.  The FDA and the Centers
for Disease  Control and  Prevention  ("CDC") have  investigated  an incident in
which a patient who received a  Tutoplast(R)  Dura Mater  transplant in 1992 was
diagnosed with CJD in 1998. Although there have been no other reports of disease
transmission  associated with over 500,000  Tutoplast(R) Dura Mater transplants,
based on the investigation conducted by FDA and CDC, the Company cannot rule out
with absolute  certainty at this time that Tutoplast(R) Dura Mater may have been
the possible cause of CJD in this incident.


                                        7
<PAGE>


Consequently, the Company has voluntarily recalled from the market all sizes and
lots of Tutoplast(R)  Dura Mater processed in Germany before 1994 under the same
conditions as the lot that is the subject of FDA's  concern.  All sizes and lots
of Tutoplast(R) Dura Mater bearing an expiration date after April 1999 that were
processed by the  Company's  US  operation  at its facility in Alachua,  Florida
since  April  1994,  under  conditions  that  meet  current  United  States  and
International standards and regulatory requirements, are not involved. There has
been no recall requested by the German health  authorities.  However,  they have
raised the regulatory  requirements on dura mater.  The Company will comply with
these new requirements.

There have been  minimal  returns of product in the U.S.,  it will take  several
weeks to comply with the new requirements in Germany.  Meanwhile, the Company is
offering  alternative  tissues such as fascia lata and bovine pericardium to the
market.  Nevertheless,  the  impact of the delay in  supplies  caused by the new
requirements on dura mater is estimated to be a loss of $350,000 in revenues and
reduced profits of $210,000 for the fiscal year.

Year 2000 Compliance

Management  has recently  become aware that one of the operating  systems in the
International operations is not currently Year 2000 compliant. The International
operation is currently implementing a new operating system, which will encompass
the  necessary  amendments  for the system to become  Year 2000  compliant.  The
implementation  is expected to be completed by September  1999. The costs of the
Year  2000  upgrade  are  included  in  the  overall  implementation  cost,  and
therefore, are not separately identifiable.


                                        8
<PAGE>


     PART II. OTHER INFORMATION


     Item 6. Exhibits and Reports on Form 8-K.

             Exhibits

             No. 27    Financial Data Schedule

             No  reports  on Form 8-K were  filed by the  Company  during  the
             quarter ended June 30, 1999.


                                        9
<PAGE>


SIGNATURES

Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
Pursuant to the  requirements  of the  Securities  and Exchange Act of 1934, the
undersigned, thereunto duly authorized.

                                                 Tutogen Medical, Inc.




Date:  August 9, 1999                            /s/ Charles C. Dragone
                                                 -------------------------------
                                                 Interim Chief Executive Officer




Date:  August 9, 1999                            /s/ George Lombardi
                                                 -------------------------------
                                                 Chief Financial Officer
                                                 (Principal Financial and
                                                  Accounting Officer)


                                       10